CLBX — Cellbxhealth Share News
0.000.00%
Last trade - 00:00- £17.38m
- £15.77m
- £2.86m
Preliminary Results
Study of ovarian cancer CTCs using Parsortix
New commercial agreement with large pharma
Brief: Angle Signs New Commercial Agreement With Astrazeneca
New commercial agreement with AstraZeneca
Parsortix HER2 assay showcased at AACR 2024
Parsortix at European breast cancer conference
Potential utility in precision oncology
Europe Research Roundup: Atlas Copco, Qinetiq Group Plc, WH Smith Plc
Standard form for notification of major holdings
Brief: Angle Plc Announces Results From DNA Molecular Analysis Of Cancer Patient Blood Samples
Contract announcement with Eisai Inc.
Parsortix unlocks opportunities for drug discovery
ANGLE launches Portrait+ CTC kit at SABCS
Launch of PD-L1 test to support cancer studies
Trading and business update
Supporting characterisation of CTCs in HNSCC
Parsortix outperforms standard for DTC harvest
Parsortix system showcased at ACTC conference